Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Hood

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nature Reviews. Cancer|March 15, 2003
Role of integrins in cell invasion and migrationJohn D Hood, David A Cheresh
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2003
Building a better TrapJohn D Hood, David A Cheresh
Science (New York, N.Y.)|July 5, 2003
Role of Raf in vascular protection from distinct apoptotic stimuliAlireza Alavi, John D Hood, Ricardo Frausto, et al.
The Journal of Cell Biology|September 4, 2003
Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesisJohn D Hood, Ricardo Frausto, William B Kiosses, et al.
Science (New York, N.Y.)|June 29, 2002
Tumor regression by targeted gene delivery to the neovasculatureJohn D Hood, Mark Bednarski, Ricardo Frausto, et al.
The Journal of Cell Biology|April 3, 2002
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signalingBrian P Eliceiri, Xose S Puente, John D Hood, et al.
Cancer Cell|April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitorsIfat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.
Blood|May 16, 2008
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemiaIlaria V Libani, Ella C Guy, Luca Melchiori, et al.
Cancer Cell|April 9, 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig, Michael G Kharas, Rachel Okabe, et al.
Journal of Medicinal Chemistry|March 4, 2008
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degenerationMoorthy S S Palanki, Hideo Akiyama, Peter Campochiaro, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Reviews. Cancer|March 15, 2003
Role of integrins in cell invasion and migrationJohn D Hood, David A Cheresh
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2003
Building a better TrapJohn D Hood, David A Cheresh
Science (New York, N.Y.)|July 5, 2003
Role of Raf in vascular protection from distinct apoptotic stimuliAlireza Alavi, John D Hood, Ricardo Frausto, et al.
The Journal of Cell Biology|September 4, 2003
Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesisJohn D Hood, Ricardo Frausto, William B Kiosses, et al.
Science (New York, N.Y.)|June 29, 2002
Tumor regression by targeted gene delivery to the neovasculatureJohn D Hood, Mark Bednarski, Ricardo Frausto, et al.
The Journal of Cell Biology|April 3, 2002
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signalingBrian P Eliceiri, Xose S Puente, John D Hood, et al.
Cancer Cell|April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitorsIfat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.
Blood|May 16, 2008
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemiaIlaria V Libani, Ella C Guy, Luca Melchiori, et al.
Cancer Cell|April 9, 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig, Michael G Kharas, Rachel Okabe, et al.
Journal of Medicinal Chemistry|March 4, 2008
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degenerationMoorthy S S Palanki, Hideo Akiyama, Peter Campochiaro, et al.
Pageof 2